Global Generic Drugs Market Analysis and Forecast 2024-2030

Global Generic Drugs Market Analysis and Forecast 2024-2030


Summary

A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.

According to APO Research, The global Generic Drugs market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global companies of Generic Drugs include Teva, Novartis - Sandoz, Mylan, Sun Pharmaceutical, Aspen, Fresenius Kabi, Pfizer (Hospira), Sanofi and Aurobindo, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Generic Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Generic Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Generic Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Generic Drugs revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Generic Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Generic Drugs revenue, projected growth trends, production technology, application and end-user industry.

Generic Drugs segment by Company

Teva
Novartis - Sandoz
Mylan
Sun Pharmaceutical
Aspen
Fresenius Kabi
Pfizer (Hospira)
Sanofi
Aurobindo
Lupin
Dr. Reddy's
Apotex
Cipla
ENDO (Par Pharmaceutical)
Stada Arzneimittel
Krka Group
Nichi-Iko Pharmaceutical
Valeant
Zydus Cadila
Hikma
Pharmaniaga Berhad
Hovid Berhad
Duopharma Biotech
Kotra Pharma
HOE Pharmaceutical
Y.S.P. Industries
Generic Drugs segment by Type

Prescription
Non-Prescription Drugs
Generic Drugs segment by Application

Hospital
Clinic
Others
Generic Drugs segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Generic Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Generic Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Generic Drugs revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.


1 Market Overview
1.1 Product Definition
1.2 Generic Drugs Market by Type
1.2.1 Global Generic Drugs Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Prescription
1.2.3 Non-Prescription Drugs
1.3 Generic Drugs Market by Application
1.3.1 Global Generic Drugs Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Generic Drugs Market Dynamics
2.1 Generic Drugs Industry Trends
2.2 Generic Drugs Industry Drivers
2.3 Generic Drugs Industry Opportunities and Challenges
2.4 Generic Drugs Industry Restraints
3 Global Growth Perspective
3.1 Global Generic Drugs Market Perspective (2019-2030)
3.2 Global Generic Drugs Growth Trends by Region
3.2.1 Global Generic Drugs Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Generic Drugs Market Size by Region (2019-2024)
3.2.3 Global Generic Drugs Market Size by Region (2025-2030)
4 Competitive Landscape by Players
4.1 Global Generic Drugs Revenue by Players
4.1.1 Global Generic Drugs Revenue by Players (2019-2024)
4.1.2 Global Generic Drugs Revenue Market Share by Players (2019-2024)
4.1.3 Global Generic Drugs Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Generic Drugs Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Generic Drugs Key Players Headquarters & Area Served
4.4 Global Generic Drugs Players, Product Type & Application
4.5 Global Generic Drugs Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Generic Drugs Market CR5 and HHI
4.6.2 Global Top 5 and 10 Generic Drugs Players Market Share by Revenue in 2023
4.6.3 2023 Generic Drugs Tier 1, Tier 2, and Tier 3
5 Generic Drugs Market Size by Type
5.1 Global Generic Drugs Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Generic Drugs Revenue by Type (2019-2030)
5.3 Global Generic Drugs Revenue Market Share by Type (2019-2030)
6 Generic Drugs Market Size by Application
6.1 Global Generic Drugs Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Generic Drugs Revenue by Application (2019-2030)
6.3 Global Generic Drugs Revenue Market Share by Application (2019-2030)
7 Company Profiles
7.1 Teva
7.1.1 Teva Comapny Information
7.1.2 Teva Business Overview
7.1.3 Teva Generic Drugs Revenue and Gross Margin (2019-2024)
7.1.4 Teva Generic Drugs Product Portfolio
7.1.5 Teva Recent Developments
7.2 Novartis - Sandoz
7.2.1 Novartis - Sandoz Comapny Information
7.2.2 Novartis - Sandoz Business Overview
7.2.3 Novartis - Sandoz Generic Drugs Revenue and Gross Margin (2019-2024)
7.2.4 Novartis - Sandoz Generic Drugs Product Portfolio
7.2.5 Novartis - Sandoz Recent Developments
7.3 Mylan
7.3.1 Mylan Comapny Information
7.3.2 Mylan Business Overview
7.3.3 Mylan Generic Drugs Revenue and Gross Margin (2019-2024)
7.3.4 Mylan Generic Drugs Product Portfolio
7.3.5 Mylan Recent Developments
7.4 Sun Pharmaceutical
7.4.1 Sun Pharmaceutical Comapny Information
7.4.2 Sun Pharmaceutical Business Overview
7.4.3 Sun Pharmaceutical Generic Drugs Revenue and Gross Margin (2019-2024)
7.4.4 Sun Pharmaceutical Generic Drugs Product Portfolio
7.4.5 Sun Pharmaceutical Recent Developments
7.5 Aspen
7.5.1 Aspen Comapny Information
7.5.2 Aspen Business Overview
7.5.3 Aspen Generic Drugs Revenue and Gross Margin (2019-2024)
7.5.4 Aspen Generic Drugs Product Portfolio
7.5.5 Aspen Recent Developments
7.6 Fresenius Kabi
7.6.1 Fresenius Kabi Comapny Information
7.6.2 Fresenius Kabi Business Overview
7.6.3 Fresenius Kabi Generic Drugs Revenue and Gross Margin (2019-2024)
7.6.4 Fresenius Kabi Generic Drugs Product Portfolio
7.6.5 Fresenius Kabi Recent Developments
7.7 Pfizer (Hospira)
7.7.1 Pfizer (Hospira) Comapny Information
7.7.2 Pfizer (Hospira) Business Overview
7.7.3 Pfizer (Hospira) Generic Drugs Revenue and Gross Margin (2019-2024)
7.7.4 Pfizer (Hospira) Generic Drugs Product Portfolio
7.7.5 Pfizer (Hospira) Recent Developments
7.8 Sanofi
7.8.1 Sanofi Comapny Information
7.8.2 Sanofi Business Overview
7.8.3 Sanofi Generic Drugs Revenue and Gross Margin (2019-2024)
7.8.4 Sanofi Generic Drugs Product Portfolio
7.8.5 Sanofi Recent Developments
7.9 Aurobindo
7.9.1 Aurobindo Comapny Information
7.9.2 Aurobindo Business Overview
7.9.3 Aurobindo Generic Drugs Revenue and Gross Margin (2019-2024)
7.9.4 Aurobindo Generic Drugs Product Portfolio
7.9.5 Aurobindo Recent Developments
7.10 Lupin
7.10.1 Lupin Comapny Information
7.10.2 Lupin Business Overview
7.10.3 Lupin Generic Drugs Revenue and Gross Margin (2019-2024)
7.10.4 Lupin Generic Drugs Product Portfolio
7.10.5 Lupin Recent Developments
7.11 Dr. Reddy's
7.11.1 Dr. Reddy's Comapny Information
7.11.2 Dr. Reddy's Business Overview
7.11.3 Dr. Reddy's Generic Drugs Revenue and Gross Margin (2019-2024)
7.11.4 Dr. Reddy's Generic Drugs Product Portfolio
7.11.5 Dr. Reddy's Recent Developments
7.12 Apotex
7.12.1 Apotex Comapny Information
7.12.2 Apotex Business Overview
7.12.3 Apotex Generic Drugs Revenue and Gross Margin (2019-2024)
7.12.4 Apotex Generic Drugs Product Portfolio
7.12.5 Apotex Recent Developments
7.13 Cipla
7.13.1 Cipla Comapny Information
7.13.2 Cipla Business Overview
7.13.3 Cipla Generic Drugs Revenue and Gross Margin (2019-2024)
7.13.4 Cipla Generic Drugs Product Portfolio
7.13.5 Cipla Recent Developments
7.14 ENDO (Par Pharmaceutical)
7.14.1 ENDO (Par Pharmaceutical) Comapny Information
7.14.2 ENDO (Par Pharmaceutical) Business Overview
7.14.3 ENDO (Par Pharmaceutical) Generic Drugs Revenue and Gross Margin (2019-2024)
7.14.4 ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio
7.14.5 ENDO (Par Pharmaceutical) Recent Developments
7.15 Stada Arzneimittel
7.15.1 Stada Arzneimittel Comapny Information
7.15.2 Stada Arzneimittel Business Overview
7.15.3 Stada Arzneimittel Generic Drugs Revenue and Gross Margin (2019-2024)
7.15.4 Stada Arzneimittel Generic Drugs Product Portfolio
7.15.5 Stada Arzneimittel Recent Developments
7.16 Krka Group
7.16.1 Krka Group Comapny Information
7.16.2 Krka Group Business Overview
7.16.3 Krka Group Generic Drugs Revenue and Gross Margin (2019-2024)
7.16.4 Krka Group Generic Drugs Product Portfolio
7.16.5 Krka Group Recent Developments
7.17 Nichi-Iko Pharmaceutical
7.17.1 Nichi-Iko Pharmaceutical Comapny Information
7.17.2 Nichi-Iko Pharmaceutical Business Overview
7.17.3 Nichi-Iko Pharmaceutical Generic Drugs Revenue and Gross Margin (2019-2024)
7.17.4 Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio
7.17.5 Nichi-Iko Pharmaceutical Recent Developments
7.18 Valeant
7.18.1 Valeant Comapny Information
7.18.2 Valeant Business Overview
7.18.3 Valeant Generic Drugs Revenue and Gross Margin (2019-2024)
7.18.4 Valeant Generic Drugs Product Portfolio
7.18.5 Valeant Recent Developments
7.19 Zydus Cadila
7.19.1 Zydus Cadila Comapny Information
7.19.2 Zydus Cadila Business Overview
7.19.3 Zydus Cadila Generic Drugs Revenue and Gross Margin (2019-2024)
7.19.4 Zydus Cadila Generic Drugs Product Portfolio
7.19.5 Zydus Cadila Recent Developments
7.20 Hikma
7.20.1 Hikma Comapny Information
7.20.2 Hikma Business Overview
7.20.3 Hikma Generic Drugs Revenue and Gross Margin (2019-2024)
7.20.4 Hikma Generic Drugs Product Portfolio
7.20.5 Hikma Recent Developments
7.21 Pharmaniaga Berhad
7.21.1 Pharmaniaga Berhad Comapny Information
7.21.2 Pharmaniaga Berhad Business Overview
7.21.3 Pharmaniaga Berhad Generic Drugs Revenue and Gross Margin (2019-2024)
7.21.4 Pharmaniaga Berhad Generic Drugs Product Portfolio
7.21.5 Pharmaniaga Berhad Recent Developments
7.22 Hovid Berhad
7.22.1 Hovid Berhad Comapny Information
7.22.2 Hovid Berhad Business Overview
7.22.3 Hovid Berhad Generic Drugs Revenue and Gross Margin (2019-2024)
7.22.4 Hovid Berhad Generic Drugs Product Portfolio
7.22.5 Hovid Berhad Recent Developments
7.23 Duopharma Biotech
7.23.1 Duopharma Biotech Comapny Information
7.23.2 Duopharma Biotech Business Overview
7.23.3 Duopharma Biotech Generic Drugs Revenue and Gross Margin (2019-2024)
7.23.4 Duopharma Biotech Generic Drugs Product Portfolio
7.23.5 Duopharma Biotech Recent Developments
7.24 Kotra Pharma
7.24.1 Kotra Pharma Comapny Information
7.24.2 Kotra Pharma Business Overview
7.24.3 Kotra Pharma Generic Drugs Revenue and Gross Margin (2019-2024)
7.24.4 Kotra Pharma Generic Drugs Product Portfolio
7.24.5 Kotra Pharma Recent Developments
7.25 HOE Pharmaceutical
7.25.1 HOE Pharmaceutical Comapny Information
7.25.2 HOE Pharmaceutical Business Overview
7.25.3 HOE Pharmaceutical Generic Drugs Revenue and Gross Margin (2019-2024)
7.25.4 HOE Pharmaceutical Generic Drugs Product Portfolio
7.25.5 HOE Pharmaceutical Recent Developments
7.26 Y.S.P. Industries
7.26.1 Y.S.P. Industries Comapny Information
7.26.2 Y.S.P. Industries Business Overview
7.26.3 Y.S.P. Industries Generic Drugs Revenue and Gross Margin (2019-2024)
7.26.4 Y.S.P. Industries Generic Drugs Product Portfolio
7.26.5 Y.S.P. Industries Recent Developments
8 North America
8.1 North America Generic Drugs Revenue (2019-2030)
8.2 North America Generic Drugs Revenue by Type (2019-2030)
8.2.1 North America Generic Drugs Revenue by Type (2019-2024)
8.2.2 North America Generic Drugs Revenue by Type (2025-2030)
8.3 North America Generic Drugs Revenue Share by Type (2019-2030)
8.4 North America Generic Drugs Revenue by Application (2019-2030)
8.4.1 North America Generic Drugs Revenue by Application (2019-2024)
8.4.2 North America Generic Drugs Revenue by Application (2025-2030)
8.5 North America Generic Drugs Revenue Share by Application (2019-2030)
8.6 North America Generic Drugs Revenue by Country
8.6.1 North America Generic Drugs Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Generic Drugs Revenue by Country (2019-2024)
8.6.3 North America Generic Drugs Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 Europe
9.1 Europe Generic Drugs Revenue (2019-2030)
9.2 Europe Generic Drugs Revenue by Type (2019-2030)
9.2.1 Europe Generic Drugs Revenue by Type (2019-2024)
9.2.2 Europe Generic Drugs Revenue by Type (2025-2030)
9.3 Europe Generic Drugs Revenue Share by Type (2019-2030)
9.4 Europe Generic Drugs Revenue by Application (2019-2030)
9.4.1 Europe Generic Drugs Revenue by Application (2019-2024)
9.4.2 Europe Generic Drugs Revenue by Application (2025-2030)
9.5 Europe Generic Drugs Revenue Share by Application (2019-2030)
9.6 Europe Generic Drugs Revenue by Country
9.6.1 Europe Generic Drugs Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Generic Drugs Revenue by Country (2019-2024)
9.6.3 Europe Generic Drugs Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 China
10.1 China Generic Drugs Revenue (2019-2030)
10.2 China Generic Drugs Revenue by Type (2019-2030)
10.2.1 China Generic Drugs Revenue by Type (2019-2024)
10.2.2 China Generic Drugs Revenue by Type (2025-2030)
10.3 China Generic Drugs Revenue Share by Type (2019-2030)
10.4 China Generic Drugs Revenue by Application (2019-2030)
10.4.1 China Generic Drugs Revenue by Application (2019-2024)
10.4.2 China Generic Drugs Revenue by Application (2025-2030)
10.5 China Generic Drugs Revenue Share by Application (2019-2030)
11 Asia (Excluding China)
11.1 Asia Generic Drugs Revenue (2019-2030)
11.2 Asia Generic Drugs Revenue by Type (2019-2030)
11.2.1 Asia Generic Drugs Revenue by Type (2019-2024)
11.2.2 Asia Generic Drugs Revenue by Type (2025-2030)
11.3 Asia Generic Drugs Revenue Share by Type (2019-2030)
11.4 Asia Generic Drugs Revenue by Application (2019-2030)
11.4.1 Asia Generic Drugs Revenue by Application (2019-2024)
11.4.2 Asia Generic Drugs Revenue by Application (2025-2030)
11.5 Asia Generic Drugs Revenue Share by Application (2019-2030)
11.6 Asia Generic Drugs Revenue by Country
11.6.1 Asia Generic Drugs Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Generic Drugs Revenue by Country (2019-2024)
11.6.3 Asia Generic Drugs Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 Middle East, Africa, Latin America
12.1 MEALA Generic Drugs Revenue (2019-2030)
12.2 MEALA Generic Drugs Revenue by Type (2019-2030)
12.2.1 MEALA Generic Drugs Revenue by Type (2019-2024)
12.2.2 MEALA Generic Drugs Revenue by Type (2025-2030)
12.3 MEALA Generic Drugs Revenue Share by Type (2019-2030)
12.4 MEALA Generic Drugs Revenue by Application (2019-2030)
12.4.1 MEALA Generic Drugs Revenue by Application (2019-2024)
12.4.2 MEALA Generic Drugs Revenue by Application (2025-2030)
12.5 MEALA Generic Drugs Revenue Share by Application (2019-2030)
12.6 MEALA Generic Drugs Revenue by Country
12.6.1 MEALA Generic Drugs Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Generic Drugs Revenue by Country (2019-2024)
12.6.3 MEALA Generic Drugs Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings